• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

紫杉醇增强溶瘤腺病毒的复制和穿透以根除胃癌腹膜转移

Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer.

作者信息

Ishikawa Wataru, Kikuchi Satoru, Ogawa Toshihiro, Tabuchi Motoyasu, Tazawa Hiroshi, Kuroda Shinji, Noma Kazuhiro, Nishizaki Masahiko, Kagawa Shunsuke, Urata Yasuo, Fujiwara Toshiyoshi

机构信息

Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.

Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama 700-8558, Japan.

出版信息

Mol Ther Oncolytics. 2020 Jun 25;18:262-271. doi: 10.1016/j.omto.2020.06.021. eCollection 2020 Sep 25.

DOI:10.1016/j.omto.2020.06.021
PMID:32728614
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7378855/
Abstract

Peritoneal metastasis is the most frequent form of distant metastasis and recurrence in gastric cancer, and the prognosis is extremely poor due to the resistance of systemic chemotherapy. Here, we demonstrate that intraperitoneal (i.p.) administration of a green fluorescence protein (GFP)-expressing attenuated adenovirus with oncolytic potency (OBP-401) synergistically suppressed the peritoneal metastasis of gastric cancer in combination with paclitaxel (PTX). OBP-401 synergistically suppressed the viability of human gastric cancer cells in combination with PTX. PTX enhanced the antitumor effect of OBP-401 due to enhanced viral replication in cancer cells. The combination therapy increased induction of mitotic catastrophe, resulting in accelerated autophagy and apoptosis. Peritoneally disseminated nodules were selectively visualized as GFP-positive spots by i.p. administration of OBP-401 in an orthotopic human gastric cancer peritoneal dissemination model. PTX enhanced the deep penetration of OBP-401 into the disseminated nodules. Moreover, a non-invasive imaging system demonstrated that the combination therapy of i.p. OBP-401 administration with PTX significantly inhibited growth of peritoneal metastatic tumors and the amount of malignant ascites. i.p. virotherapy with PTX may be a promising treatment strategy for the peritoneal metastasis of gastric cancer.

摘要

腹膜转移是胃癌远处转移和复发最常见的形式,由于全身化疗耐药,其预后极差。在此,我们证明腹腔内(i.p.)给予具有溶瘤效力的绿色荧光蛋白(GFP)表达减毒腺病毒(OBP-401)与紫杉醇(PTX)联合可协同抑制胃癌的腹膜转移。OBP-401与PTX联合可协同抑制人胃癌细胞的活力。由于癌细胞中病毒复制增强,PTX增强了OBP-401的抗肿瘤作用。联合治疗增加了有丝分裂灾难的诱导,导致自噬和凋亡加速。在原位人胃癌腹膜播散模型中,通过腹腔内给予OBP-401,腹膜播散结节被选择性地可视化为GFP阳性斑点。PTX增强了OBP-401向播散结节的深度渗透。此外,一种非侵入性成像系统表明,腹腔内给予OBP-401与PTX的联合治疗显著抑制了腹膜转移性肿瘤的生长和恶性腹水的量。PTX腹腔内病毒疗法可能是治疗胃癌腹膜转移的一种有前景的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/1526bed9ab6f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/2ded073a7fb6/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/c601c7c7641f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/c94b87ee1d36/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/63b5f598cc36/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/20caa4291edd/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/fac16531e63d/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/1526bed9ab6f/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/2ded073a7fb6/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/c601c7c7641f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/c94b87ee1d36/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/63b5f598cc36/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/20caa4291edd/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/fac16531e63d/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5626/7378855/1526bed9ab6f/gr6.jpg

相似文献

1
Boosting Replication and Penetration of Oncolytic Adenovirus by Paclitaxel Eradicate Peritoneal Metastasis of Gastric Cancer.紫杉醇增强溶瘤腺病毒的复制和穿透以根除胃癌腹膜转移
Mol Ther Oncolytics. 2020 Jun 25;18:262-271. doi: 10.1016/j.omto.2020.06.021. eCollection 2020 Sep 25.
2
Modulation of expression in cancer-associated fibroblasts prevents peritoneal metastasis of gastric cancer.调节癌症相关成纤维细胞中的表达可预防胃癌的腹膜转移。
Mol Ther Oncolytics. 2022 Apr 25;25:249-261. doi: 10.1016/j.omto.2022.04.009. eCollection 2022 Jun 16.
3
Intraperitoneal Administration of p53-armed Oncolytic Adenovirus Inhibits Peritoneal Metastasis of Diffuse-type Gastric Cancer Cells.腹腔内给予 p53 武装溶瘤腺病毒抑制弥漫型胃癌细胞的腹膜转移。
Anticancer Res. 2023 Nov;43(11):4809-4821. doi: 10.21873/anticanres.16678.
4
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.对于伴有恶性腹水的晚期胃癌腹膜转移患者,静脉和腹腔内给予紫杉醇(PTX)后,采用 S-1 口服治疗以进行挽救性胃切除术。
Ann Surg Oncol. 2014 Feb;21(2):539-46. doi: 10.1245/s10434-013-3208-y. Epub 2013 Aug 22.
5
Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.纳米白蛋白结合型紫杉醇与腹腔内溶剂型紫杉醇对胃癌腹膜转移抗肿瘤活性的比较研究
Oncol Rep. 2014 Jul;32(1):89-96. doi: 10.3892/or.2014.3210. Epub 2014 May 23.
6
Synergistic antitumor effect mediated by a paclitaxel-conjugated polymeric micelle-coated oncolytic adenovirus.载紫杉醇聚合物胶束的溶瘤腺病毒协同抗肿瘤作用。
Biomaterials. 2017 Nov;145:207-222. doi: 10.1016/j.biomaterials.2017.08.035. Epub 2017 Aug 23.
7
Downregulation of CDH11 Promotes Metastasis and Resistance to Paclitaxel in Gastric Cancer Cells.CDH11的下调促进胃癌细胞的转移和对紫杉醇的耐药性。
J Cancer. 2021 Jan 1;12(1):65-75. doi: 10.7150/jca.48193. eCollection 2021.
8
Therapeutic Cell-Cycle-Decoy Efficacy of a Telomerase-Dependent Adenovirus in an Orthotopic Model of Chemotherapy-Resistant Human Stomach Carcinomatosis Peritonitis Visualized With FUCCI Imaging.利用FUCCI成像在化疗耐药性人胃癌腹膜转移原位模型中评估端粒酶依赖性腺病毒的治疗性细胞周期诱饵疗效。
J Cell Biochem. 2017 Nov;118(11):3635-3642. doi: 10.1002/jcb.25593. Epub 2017 Jul 31.
9
Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy.骨肉瘤和软组织肉瘤:端粒酶特异性溶瘤病毒疗法的新靶点。
Cancers (Basel). 2020 Feb 18;12(2):478. doi: 10.3390/cancers12020478.
10
A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.紫杉醇静脉滴注联合腹腔内 S-1 治疗伴有腹膜转移的胃癌的Ⅱ期临床试验。
Cancer. 2013 Sep 15;119(18):3354-8. doi: 10.1002/cncr.28204. Epub 2013 Jun 24.

引用本文的文献

1
Adenoviruses Encapsulated in PEGylated DOTAP-Folate Liposomes Are Protected from the Pre-Existing Humoral Immune Response.包裹于聚乙二醇化的DOTAP-叶酸脂质体中的腺病毒可免受预先存在的体液免疫反应的影响。
Pharmaceutics. 2025 Jun 11;17(6):769. doi: 10.3390/pharmaceutics17060769.
2
Advancements and challenges in immunotherapy for gastric cancer: current approaches and future directions.胃癌免疫治疗的进展与挑战:当前方法与未来方向
Front Immunol. 2025 May 21;16:1592733. doi: 10.3389/fimmu.2025.1592733. eCollection 2025.
3
Dasatinib demonstrates efficacy in organoid derived paclitaxel-resistant Trp53/Cdh1-deficient mouse gastric adenocarcinoma with peritoneal metastasis.

本文引用的文献

1
Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody.端粒酶特异性溶瘤腺病毒的免疫调节作用与抗 PD1 抗体协同增强抗肿瘤疗效。
Mol Ther. 2020 Mar 4;28(3):794-804. doi: 10.1016/j.ymthe.2020.01.003. Epub 2020 Jan 10.
2
The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer.肿瘤相关巨噬细胞诱导的上皮-间充质转化赋予腹膜扩散性胰腺癌的化疗耐药性。
J Exp Clin Cancer Res. 2018 Dec 11;37(1):307. doi: 10.1186/s13046-018-0981-2.
3
Integrated fluorescent cytology with nano-biologics in peritoneally disseminated gastric cancer.
达沙替尼对源自携带腹膜转移的Trp53/Cdh1缺陷型小鼠胃腺癌的类器官紫杉醇耐药模型显示出疗效。
Cell Regen. 2025 Apr 29;14(1):16. doi: 10.1186/s13619-025-00232-2.
4
Potential mechanism of traditional Chinese medicine intervention in gastric cancer: targeted regulation of autophagy.中医药干预胃癌的潜在机制:自噬的靶向调控
Front Pharmacol. 2025 Feb 18;16:1548672. doi: 10.3389/fphar.2025.1548672. eCollection 2025.
5
Arrest and Attack: Microtubule-Targeting Agents and Oncolytic Viruses Employ Complementary Mechanisms to Enhance Anti-Tumor Therapy Efficacy.抑制与攻击:微管靶向药物与溶瘤病毒利用互补机制增强抗肿瘤治疗效果。
Genes (Basel). 2024 Sep 11;15(9):1193. doi: 10.3390/genes15091193.
6
Functional remodeling of intraperitoneal macrophages by oncolytic adenovirus restores anti-tumor immunity for peritoneal metastasis of gastric cancer.溶瘤腺病毒对腹腔巨噬细胞的功能重塑可恢复胃癌腹膜转移的抗肿瘤免疫力。
Mol Ther Oncol. 2024 Apr 24;32(2):200806. doi: 10.1016/j.omton.2024.200806. eCollection 2024 Jun 20.
7
Emerging therapeutic approaches for peritoneal metastases from gastrointestinal cancers.胃肠道癌症腹膜转移的新兴治疗方法。
Mol Ther Oncol. 2024 Jan 29;32(1):200767. doi: 10.1016/j.omton.2024.200767. eCollection 2024 Mar 21.
8
Efficacy of Different Oncolytic Vaccinia Virus Strains for the Treatment of Murine Peritoneal Mesothelioma.不同溶瘤痘苗病毒株治疗小鼠腹膜间皮瘤的疗效
Cancers (Basel). 2024 Jan 15;16(2):368. doi: 10.3390/cancers16020368.
9
Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies.嵌合抗原受体T细胞和溶瘤病毒疗法用于胃癌及胃源性腹膜癌病:改善联合策略之路
Cancers (Basel). 2023 Nov 30;15(23):5661. doi: 10.3390/cancers15235661.
10
Regional Immunotherapy for Peritoneal Carcinomatosis in Gastroesophageal Cancer: Emerging Strategies to Re-Condition a Maladaptive Tumor Environment.食管癌腹膜转移癌的区域免疫治疗:重塑适应性不良肿瘤环境的新兴策略
Cancers (Basel). 2023 Oct 23;15(20):5107. doi: 10.3390/cancers15205107.
腹腔内播散性胃癌中荧光细胞学与纳米生物学的整合。
Cancer Sci. 2018 Oct;109(10):3263-3271. doi: 10.1111/cas.13760. Epub 2018 Sep 23.
4
Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.紫杉醇腹腔内和静脉给药联合 S-1 对比顺铂联合 S-1 治疗胃癌伴腹膜转移患者的 III 期临床试验:PHOENIX-GC 试验。
J Clin Oncol. 2018 Jul 1;36(19):1922-1929. doi: 10.1200/JCO.2018.77.8613. Epub 2018 May 10.
5
Involvement of autophagy in the outcome of mitotic catastrophe.自噬在有丝分裂灾难结局中的作用。
Sci Rep. 2017 Nov 6;7(1):14571. doi: 10.1038/s41598-017-14901-z.
6
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者(ONO-4538-12,ATTRACTION-2):一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
7
Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.伴有腹膜转移或腹膜细胞学检查结果阳性的胃癌患者在接受腹腔内和全身化疗后的手术治疗。
Gastric Cancer. 2017 Mar;20(Suppl 1):128-134. doi: 10.1007/s10120-016-0684-3. Epub 2016 Dec 27.
8
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.胃癌临床实践指南(NCCN 肿瘤学版) 2016 年第 3 版
J Natl Compr Canc Netw. 2016 Oct;14(10):1286-1312. doi: 10.6004/jnccn.2016.0137.
9
Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas.病毒诱导的 microRNA-29 对 MCL1 表达的消融可逆转人骨肉瘤的化疗耐药性。
Sci Rep. 2016 Jun 30;6:28953. doi: 10.1038/srep28953.
10
Japanese gastric cancer treatment guidelines 2014 (ver. 4).《日本胃癌治疗指南2014(第4版)》
Gastric Cancer. 2017 Jan;20(1):1-19. doi: 10.1007/s10120-016-0622-4. Epub 2016 Jun 24.